What Is a SubQ Infusion and How Does It Work?

Subcutaneous infusion, often shortened to “subq infusion,” delivers fluid or medication into the tissue layer just beneath the skin, where it is gradually absorbed into the bloodstream. Unlike an intravenous (IV) line that puts substances directly into a vein, a subq infusion relies on the body’s own capillary network to pull the delivered solution from the tissue into circulation. This slower, gentler absorption profile makes it useful across a surprisingly wide range of medical situations, from rehydrating elderly patients who cannot tolerate an IV to delivering cancer drugs and managing Parkinson’s disease symptoms at home.

How Fluid Moves From Tissue Into the Bloodstream

When fluid is infused under the skin, it pools briefly in the subcutaneous space, the fatty connective tissue that sits between the skin and muscle. From there, it crosses into nearby capillaries through passive diffusion, driven largely by the osmotic pull of albumin, the most abundant protein in blood plasma. In healthy adults with normal albumin levels, this process is efficient enough that fluid reaches the circulation within a predictable window. For medications like monoclonal antibodies, peak blood concentrations after a subq injection tend to arrive days later rather than minutes, reflecting the slow transit from tissue depot to bloodstream.¹

That delay is not a flaw. For many drugs, the sustained release from subcutaneous tissue actually smooths out blood levels, avoiding the sharp peaks and troughs that come with IV boluses. A comparison of gonadotropin-releasing hormone given by each route found that IV injection produced a fast, high spike that dropped quickly, while the subcutaneous route produced a lower, broader curve that stayed above baseline for longer.² For therapies where you want steady drug levels over time, that flatter curve is an advantage.

Rehydrating Older Adults

The oldest and most established use of subq infusion is hydration in elderly patients, a practice historically called hypodermoclysis. Many older adults in hospitals or long-term care facilities become mildly to moderately dehydrated but have fragile veins that make IV access difficult, painful, or impossible. For these patients, placing a small needle under the skin of the thigh, abdomen, or upper chest and running normal saline or a dextrose-saline solution at a moderate rate can restore hydration effectively.

A systematic review comparing hypodermoclysis to IV therapy found that both routes absorbed fluid at similar rates, and that side effects from subq infusion were generally minor when isotonic or mildly hypotonic solutions were used.³ A separate review of evidence on subcutaneous dextrose solutions reached a similar conclusion: appropriate volumes infused under the skin work well for dehydration in older people, with adverse-effect rates comparable to IV infusion.⁴

In a study of long-term care patients, clinical improvement after subq hydration occurred in about three quarters of cases, with gains in cognitive status, general alertness, and oral intake. Local complications like swelling or pain at the needle site were reported in a small minority, and nobody developed signs of fluid overload.⁵ That last point matters because fluid overload is a real risk with IV hydration in frail elderly patients, and the slower absorption of a subq infusion acts as a natural brake.

One physiological wrinkle is that many hospitalized older adults have low albumin levels due to acute illness or poor nutrition. Because albumin provides the osmotic force pulling subq fluid into capillaries, low albumin could theoretically slow absorption. An exploratory study in ill, multimorbid elderly patients investigated this question, finding that the relationship between albumin, absorption rate, and completeness of fluid uptake is still not fully understood in this population.⁶ Clinicians generally account for this by adjusting flow rates and monitoring the infusion site for excess pooling.

Immunoglobulin Therapy and Home Treatment

For people with primary or secondary immunodeficiency, regular infusions of immunoglobulin (Ig) are the backbone of treatment. Traditionally, this meant going to a hospital or infusion center every few weeks for an IV drip lasting several hours. Subcutaneous immunoglobulin (SCIg) has changed that equation. Patients or caregivers learn to set up a small pump and infuse the Ig under the skin at home, typically once a week or every two weeks, in sessions that fit around normal life.

A meta-analysis comparing SCIg to IV immunoglobulin (IVIg) in primary immunodeficiency found that subcutaneous delivery produced higher steady-state immunoglobulin levels in the blood, with a trend toward fewer side effects and similar infection rates.⁷ A separate evidence-based review confirmed that trough immunoglobulin levels were consistently higher with subcutaneous delivery.⁸ Higher trough levels mean the patient spends less time with low circulating antibodies between doses, which may explain why some patients experience fewer infections after switching from IV to SC.

Patient-reported outcomes consistently favor subcutaneous delivery. In secondary immunodeficiency, patients highlight the ease of self-administration at home, the convenience of flexible scheduling, and the time saved by not traveling to a clinic.⁹ A systematic review of patient preferences across chronic immune disorders found that those choosing subcutaneous delivery also preferred home treatment, largely because of comfort and the ability to avoid hospital visits.¹⁰

That said, home infusion has its own challenges. Some patients struggle with site reactions, which are the most common adverse event. In one documented case, infusion-site reactions turned out to be caused by improper technique, a correctable issue once medical staff identified it.¹¹ Survey data confirm that while patients overall prefer home-based subcutaneous infusion, the process presents practical difficulties that manufacturers and clinicians are still working to streamline.¹²

Cancer Drugs and Monoclonal Antibodies

Oncology has embraced subcutaneous delivery for several monoclonal antibodies. Trastuzumab, a cornerstone treatment for HER2-positive breast cancer, was one of the first to make the switch. The subcutaneous version takes about five minutes to inject compared to the 30–90 minutes needed for an IV infusion, and it uses a fixed dose rather than a weight-based calculation, reducing preparation time and the chance of dosing errors.¹³ Studies have confirmed that subcutaneous monoclonal antibodies in oncology offer comparable therapeutic effectiveness to their IV counterparts.¹⁴

The pharmacokinetic profiles do differ between routes. Subcutaneous delivery produces a slower rise to peak concentration and sometimes lower peak levels, but the total drug exposure over time is generally sufficient for efficacy. Across multiple biotherapeutics, subcutaneous administration has proven effective, safe, well-tolerated, and generally preferred by both patients and healthcare providers.¹⁵

One ongoing challenge in formulation science is volume. A typical subq injection site can comfortably accept only about 1–2 milliliters of fluid, which means high-dose biologics must be concentrated into very small volumes. That creates formulation headaches: highly concentrated protein solutions can become viscous, difficult to inject, and prone to aggregation. Researchers are exploring alternative delivery systems that support larger volumes at lower concentrations to sidestep these problems.¹⁶

Insulin Pumps and Continuous Subcutaneous Delivery

The most familiar subq infusion device in everyday life is the insulin pump. Continuous subcutaneous insulin infusion (CSII) delivers rapid-acting insulin through a tiny cannula under the skin, programmed to release a steady basal rate with additional boluses at meals. Compared to multiple daily injections, insulin pumps provide more consistent basal delivery, adjustable rates for exercise or sleep, and smaller insulin depots in tissue.¹⁷

A meta-analysis of individual patient data from randomized trials in type 2 diabetes found that CSII achieved better blood sugar control than multiple daily injections, with roughly a 26% reduction in total insulin requirements and no difference in weight gain.¹⁸ The biggest improvements appeared in people who had the worst control and highest insulin doses at baseline, suggesting that CSII is especially valuable for patients who struggle to manage blood sugar with injections alone.

Proper injection site management matters for anyone using subq insulin, whether by pump or syringe. Repeatedly injecting into the same spot causes lipohypertrophy, a buildup of fatty lumps under the skin that disrupts insulin absorption and leads to erratic blood sugar swings. Systematic site rotation is the strongest modifiable way to prevent this, along with using a fresh needle each time.¹⁹ Despite the importance of rotation, a cross-sectional study of nurses found that more than half did not use a rotation chart when giving subcutaneous injections.²⁰

Palliative Care and Pain Control

When patients near the end of life lose the ability to take oral medications due to nausea, confusion, or reduced consciousness, continuous subcutaneous infusion of opioids becomes a critical tool. A portable syringe driver delivers a steady stream of pain medication under the skin, keeping the patient comfortable without requiring an IV line that can be cumbersome and distressing in a home or hospice setting.

At a tertiary palliative care center, starting a continuous subcutaneous opioid infusion cut the proportion of patients experiencing severe or overwhelming pain from 45% to 19%, with only modest increases in opioid doses. Alertness dropped slightly but performance status and rates of delirium remained unchanged, and no serious adverse effects required stopping treatment.²¹ An earlier study in cancer patients found that nearly all preferred the subcutaneous infusion system to their previous oral pain regimens, and nausea remained well controlled even as doses were increased.²²

Parkinson’s Disease

Continuous subcutaneous apomorphine infusion (CSAI) addresses one of the most frustrating aspects of advanced Parkinson’s disease: motor fluctuations, the unpredictable swings between “on” periods when medication is working and “off” periods when tremor, stiffness, and slowness return. A wearable pump delivers apomorphine, a potent dopamine agonist, steadily under the skin throughout the day.

In the phase 3 InfusON trial, patients using CSAI saw their daily “off” time drop by an average of three hours and their “good on” time increase by a similar amount within 12 weeks. About two-thirds of patients rated themselves as much or very much improved, and oral levodopa doses were meaningfully reduced. These improvements held through a full year of follow-up.²³

Pediatric Rehydration

Getting an IV into a dehydrated toddler is one of the most stressful procedures in emergency medicine, for the child, the parents, and the clinician. Small veins collapse easily, and multiple failed attempts are common. Subcutaneous rehydration, especially when facilitated with recombinant human hyaluronidase (an enzyme that temporarily loosens the tissue to allow faster fluid absorption), offers an alternative that is quicker to set up and less traumatic.

In a study of children averaging about two years old, initial subcutaneous catheter placement succeeded on the first attempt in 90% of cases, and rehydration was successful in 94% of patients when including those who received the bulk of their fluids subcutaneously before being admitted for other reasons. Investigators rated the procedure easy to perform for 96% of patients, and 90% of parents were satisfied or very satisfied.²⁴ A randomized trial comparing hyaluronidase-facilitated subcutaneous rehydration to IV rehydration in children with mild to moderate dehydration concluded that the subcutaneous route is a reasonable option, particularly when IV access is difficult.²⁵ A cost-effectiveness analysis of that same trial data found a 93% treatment success rate with the subcutaneous route versus 76% for IV, with shorter emergency department stays and lower costs, especially in children under three.²⁶

How Hyaluronidase Opens the Door

The subcutaneous space is held together by a mesh of hyaluronic acid, a gel-like molecule that gives connective tissue its structure. This mesh limits how much fluid you can push into a single site and how fast that fluid disperses. Hyaluronidase is an enzyme that temporarily breaks down hyaluronic acid, loosening the tissue matrix so fluid spreads more easily and reaches capillaries faster. The effect is reversible; the tissue rebuilds within 24 to 48 hours.

A fully human, recombinant form of hyaluronidase (rHuPH20) was developed to modernize this approach, which had been used for decades with cruder animal-derived versions. rHuPH20 increases both the volume and the bioavailability of drugs and fluids delivered subcutaneously.²⁷ Two randomized, double-blind phase 3 trials confirmed that rHuPH20 significantly increased subcutaneous infusion rates compared to placebo, with minimal increases in limb circumference at the infusion site, indicating that the fluid was dispersing into tissue rather than pooling.²⁸ This enzyme is now co-formulated with several subcutaneous biologics and is also used as a standalone pretreatment for subcutaneous hydration.

Cost and Time Savings for Health Systems

Beyond patient comfort, subcutaneous delivery frees up significant healthcare resources. A systematic review of time and resource use in hospital oncology settings found that the majority of studies showed substantial savings in preparation and administration time for subcutaneous versus IV therapy, with corresponding reductions in healthcare worker time and facility costs.²⁹

The numbers can be striking. A study of subcutaneous versus intravenous pertuzumab/trastuzumab for breast cancer found that active healthcare professional time dropped by more than half for maintenance doses. The authors estimated that nationwide adoption in their country could create capacity for roughly 22,000 additional treatments annually and save the equivalent of four full-time staff positions.³⁰ In the UK, a cost analysis across rheumatoid arthritis and inflammatory bowel disease found that total annual costs for the subcutaneous route were roughly half those of the infusion route, factoring in both direct administration costs and indirect service pressures.³¹ Subcutaneous delivery gained particular momentum during the COVID-19 pandemic, when minimizing time spent in infusion centers reduced exposure risk for immunocompromised patients.

Pumps and Devices for Home Use

Home-based subq infusion depends on reliable delivery devices. Two main categories dominate: electronic pumps, which use a motor to drive a syringe at a precisely programmed rate, and elastomeric pumps, which rely on a pressurized balloon reservoir to push fluid through tubing. Electronic pumps are more accurate but require batteries and programming. Elastomeric pumps are lightweight, silent, and disposable, making them popular for palliative care and home antibiotic therapy.

A study testing both types under conditions typical of home use found that even under ideal conditions, elastomeric pumps deviated somewhat from their stated flow rate and delivered between 88.5% and 99% of the total intended volume. Changes in height (where the pump sits relative to the patient) or back pressure from the subcutaneous tissue further affected flow rates in elastomeric pumps, while electronic pumps were largely unaffected.³² For medications with a wide therapeutic window, like hydration fluids or immunoglobulin, this variability is clinically insignificant. For drugs with a narrow therapeutic range, electronic pumps are the safer choice.

Mass Casualty and Resource-Limited Settings

When disasters overwhelm medical infrastructure, IV access becomes a bottleneck. Trained practitioners are scarce, veins are hard to find on dehydrated or injured patients in chaotic environments, and IV equipment requires sterile preparation that may not be feasible in the field. Subcutaneous infusion, especially with hyaluronidase pretreatment, has been proposed as a practical alternative for fluid resuscitation when IV lines simply cannot be placed fast enough.³³

A systematic review of systematic reviews noted that while subcutaneous hydration has not been directly studied in disaster scenarios, its ease of use and lower training requirements compared to IV access make it a reasonable recommendation for resource-limited settings, particularly for pediatric patients when intraosseous or nasogastric access is also unavailable.³⁴ The technique requires minimal equipment: a subcutaneous needle or butterfly catheter, tubing, a fluid bag, and optionally the hyaluronidase enzyme. A community health worker can be trained to set it up in a fraction of the time needed to teach IV cannulation.

Subcutaneous Fluids in Veterinary Medicine

If you have a cat with chronic kidney disease, you may already be familiar with subq infusion in a very different context. Veterinarians commonly teach cat owners to administer subcutaneous fluids at home, typically lactated Ringer’s solution or similar, to help maintain hydration between vet visits. A survey of cat owners found that the most common volume given was 100 milliliters per session. To improve tolerance, 60% warmed the fluids before infusion, and 57% offered a treat afterward. Needle size mattered: nearly half of owners said the size of the needle affected how well their cat tolerated the procedure.³⁵ The loose skin over a cat’s shoulder blades makes an ideal infusion site, and the procedure typically takes 10 to 15 minutes once the owner is comfortable with it. It is one of the clearest everyday examples of how subcutaneous infusion can be safely managed outside a clinical setting by a non-medical person.